ImmuPharma plc (LON: IMM) Chairman Tim McCarthy joins DirectorsTalk to discuss final results for the twelve months ended 31 December 2018. Tim talks us through the financial highlights, including the loss for the year and cash position. Provides guidance on spend going forward, an update on the pipeline, key milestones for the company over the next 12 months and provides some insight into an initiation note on ImmuPharma with a price target of 92p.
ImmuPharma plc is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. The company is led by a commercially focused Board and management team with extensive experience.